Please login to the form below

Not currently logged in
Email:
Password:

Erleada

This page shows the latest Erleada news and features for those working in and with pharma, biotech and healthcare.

Generic threat looms to J&J’s blockbuster Zytiga in US

Generic threat looms to J&J’s blockbuster Zytiga in US

J&J has been trying to expand its prostate cancer franchise with the launch of Erleada (apalutamide) non-metastatic CRPC. ... Erleada is one of 10 new drugs that J&J thinks could eventually make sales of more than $1bn a year.

Latest news

  • CHMP backs Sanofi’s all-oral sleeping sickness drug CHMP backs Sanofi’s all-oral sleeping sickness drug

    Johnson &Johnson got a positive opinion on its non-metastatic castration-resistant prostate cancer (CRPC) drug Erleada (apalutamide), setting up EU approval to follow its FDA green light earlier in the ... Erleada is one of ten new drug candidates that

  • Bayer preps filings for new prostate cancer drug Bayer preps filings for new prostate cancer drug

    If approved, will challenge Xtandi and Erleada. Armed with new phase 3 data, Bayer has said it intends to press ahead with regulatory filings for its anti-androgen drug darolutamide in ... Moreover, it also seems to retain activity against most androgen

  • The year of the blockbuster The year of the blockbuster

    use of medicinal cannabis exist. Erleada (apalutamide) from Johnson &Johnson:Until mid-February 2018, no FDA-approved treatment options were available for men with non-metastatic castration-resistant prostate cancer (CRPC) ... J&J’s Erleada, a

  • EMA starts review of Xtandi in non-metastatic prostate cancer EMA starts review of Xtandi in non-metastatic prostate cancer

    Pfizer and Astellas have a fight on their hands trying to tap into this new patient population, however, as J&J has already claimed approval for new therapy Erleada (apalutamide) in ... Erleada is the first to claim approval, but Xtandi benefits from

  • J&J’s Erleada first US drug for non-metastatic prostate cancer J&J’s Erleada first US drug for non-metastatic prostate cancer

    The median MFS for patients taking Erleada was 40.5 months compared to 16.2 months for the placebo arm. ... J&J acquired Erleada when it took over Aragon Pharma in 2013 in a deal valued at $1bn.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics